OTC cold-and-sinus capsule pairs analgesia with decongestant action
DailyMed’s current label for COLD AND SINUS RELIEF describes a liquid-filled oral capsule combining ibuprofen 200 mg with pseudoephedrine hydrochloride 30 mg in each dose unit. The product is positioned as a nonprescription option for temporary relief of common cold or flu symptoms, including headache, sinus pressure, nasal congestion, minor body aches and pains, and fever.
The pairing reflects a familiar symptomatic strategy in acute upper respiratory illness: one ingredient targets inflammatory pain and fever, while the other reduces mucosal congestion by constricting swollen nasal blood vessels. In practical terms, the capsule is designed for patients who want a single oral product to address both pressure and discomfort without layering multiple separate remedies.
The label also makes clear that this is not a benign combination simply because it is sold over the counter. Each active ingredient carries its own risk profile, and the warning language is explicit about who should avoid it, who should seek medical advice first, and which symptoms require discontinuation.
Dual active ingredients drive the intended symptom control
Each liquid-filled capsule contains solubilized ibuprofen equal to 200 mg ibuprofen USP, presented as the free acid and potassium salt, plus pseudoephedrine hydrochloride 30 mg. Ibuprofen functions as a pain reliever and fever reducer through nonsteroidal anti-inflammatory activity, while pseudoephedrine serves as a nasal decongestant.
The label’s dosing language follows a conventional OTC pattern: adults and children 12 years and older are directed to take one capsule every 4 to 6 hours while symptoms persist, with the option to use two capsules if one does not respond adequately. The maximum listed ceiling is six capsules in any 24-hour period unless a doctor directs otherwise. Children under 12 years are instructed not to use the product.
That ceiling matters clinically because both components can become more problematic with repeated exposure. More ibuprofen means more prostaglandin inhibition and a greater chance of gastrointestinal or renal injury; more pseudoephedrine means more adrenergic stimulation, which can aggravate blood pressure, heart rate, nervousness, or sleep disruption.
Gastrointestinal, cardiovascular, and allergy warnings remain front and center
The warning section places ibuprofen in the context of classic NSAID toxicities. A severe allergic reaction is possible, especially in people with aspirin allergy, and symptoms listed on the label include hives, facial swelling, asthma or wheezing, shock, skin reddening, rash, and blisters. If an allergic reaction occurs, use should stop immediately and medical help should be sought right away.
The stomach bleeding warning is equally direct. The risk is higher in people age 60 or older, those with a history of ulcers or bleeding problems, those taking anticoagulants or steroids, those using other prescription or nonprescription NSAIDs such as aspirin, ibuprofen, or naproxen, and those drinking three or more alcoholic beverages daily while using the product. The label also flags higher risk when the medication is taken in larger amounts or for longer than directed.
A separate warning states that NSAIDs, except aspirin, increase the risk of heart attack, heart failure, and stroke, and that these events can be fatal. A short course for a cold does not erase those risks; it simply limits exposure time. The physiologic rationale is straightforward: prostaglandin inhibition can affect vascular balance, fluid handling, and thrombotic risk in susceptible patients, particularly when doses climb above recommended limits.
Patients with cardiovascular, renal, endocrine, or urinary disease are told to ask first
Before use, the label advises speaking with a doctor if stomach bleeding warning applies, if there has been a history of serious side effects from pain relievers or fever reducers, or if a person has a history of stomach problems such as heartburn. It also advises medical consultation for people with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, trouble urinating due to an enlarged prostate gland, or prior stroke.
Pseudoephedrine explains much of that caution. As a sympathomimetic decongestant, it can raise blood pressure, worsen palpitations, and make urination more difficult in patients with prostatic enlargement. Patients already under a doctor’s care for any serious condition are also told to check before use, as are those taking any other product containing pseudoephedrine or another nasal decongestant.
There is a specific aspirin interaction warning as well. People taking aspirin for heart attack or stroke prevention are told to ask a doctor or pharmacist before use because ibuprofen may decrease aspirin’s cardioprotective benefit. Even in an OTC setting, that interaction can be clinically relevant for patients who rely on aspirin for secondary prevention.
Pregnancy, lactation, and stop-use triggers are spelled out plainly
For pregnancy and breast-feeding, the label directs patients to ask a health professional before use. It adds a particular caution against ibuprofen use at 20 weeks or later in pregnancy unless a doctor specifically directs it, because of the potential for problems in the unborn child or complications during delivery. That warning is consistent with the broader concern that NSAIDs can alter fetal renal function and amniotic fluid status later in gestation.
The stop-use instructions are broad but clinically useful. Patients are told to stop and ask a doctor if they develop signs of stomach bleeding, symptoms of heart problems or stroke, fever that lasts more than three days, nasal congestion that lasts more than seven days, symptoms that continue or worsen, redness or swelling in the painful area, nervousness, dizziness, sleeplessness, or any new symptoms. Chest pain, trouble breathing, weakness on one side of the body, slurred speech, and leg swelling are listed as urgent cardiovascular or neurologic warning signs.
Those instructions are the practical guardrails around self-treatment. OTC cold products can reduce symptom burden, but they should not blur the line between transient viral discomfort and evolving disease that needs evaluation.
Packaging, labeling status, and manufacturing details place the product in the generic OTC market
The product is listed as a human OTC drug label with abbreviated new drug application status. DailyMed identifies NDC 70000-0606-1 and 70000-0606-2, with packaging described as blister-card cartons containing liquid-filled capsules. The packager is CARDINAL HEALTH 110, LLC, doing business as LEADER, and the registrant is Aurohealth LLC. Manufacturing and analysis are listed for APL Healthcare Limited and Aurobindo Pharma Limited.
Inactive ingredients include black iron oxide, D&C yellow no. 10, gelatin, hypromellose, FD&C red no. 40, polyethylene glycol, potassium hydroxide, propylene glycol, and sorbitol sorbitan solution. The product is described as orange, oval, and marked with the imprint code IBP;200.
The label also specifies storage at 20° to 25°C and advises avoiding excessive heat above 40°C. It contains a standard overdose warning directing patients to get medical help or contact Poison Control immediately if an overdose is suspected.
For a product built around familiar ingredients, the caution language is unusually dense, and intentionally so. Cold and sinus symptoms may be common, but the safety envelope around ibuprofen and pseudoephedrine is narrow enough that label literacy still matters at the pharmacy counter and at the bedside.